194 related articles for article (PubMed ID: 4809201)
21. Heterogeneity on familial hyperlipoproteinemia type II on the basis of fasting plasma triglyceride-cholesterol ratio and plasma cholesterol response to ethyl p-chlorophenoxyisobutyrate.
Davignon J; Aubry F; Noël C; Lapierre Y; Lafortune M
Rev Can Biol; 1971 Dec; 30(4):307-18. PubMed ID: 5135408
[No Abstract] [Full Text] [Related]
22. [The treatment of essential hyperlipidemia with clofibrate].
Reuter W; Seifert A
Z Gesamte Inn Med; 1969 Jan; 24(1):Suppl:184-7. PubMed ID: 4918619
[No Abstract] [Full Text] [Related]
23. Effect of clofibrate on arginine-induced insulin and glucagon secretion.
Eaton RP
Metabolism; 1973 Jun; 22(6):763-7. PubMed ID: 4350845
[No Abstract] [Full Text] [Related]
24. [Lipoproteins, glucose tolerance and insulin secretion].
Debry G; Mejean L; Drouin P; Villaume C; Pointel JP; Vernhes G
Ann Nutr Aliment; 1979; 33(1):113-34. PubMed ID: 382956
[No Abstract] [Full Text] [Related]
25. [Differential diagnosis and differential treatment of carbohydrate tolerance disorders in patients with hyperlipoproteinemia. Behavior of plasma lipids, glucose tolerance, and plasma insulin after glucose load during treatment with clofibrate].
Bruns W; Rjasanowski I; Wulfert P; Michael R; Knospe S; Hildmann W
Endokrinologie; 1974 Nov; 64(1):2-12. PubMed ID: 4466653
[No Abstract] [Full Text] [Related]
26. Effects of oxandrolone on plasma triglycerides and postheparin lipolytic activity in patients with types 3, IV, and V familial hyperlipoproteinemia.
Glueck CJ
Metabolism; 1971 Jul; 20(7):691-702. PubMed ID: 5090133
[No Abstract] [Full Text] [Related]
27. [Effect of clofibrate on glucide tolerance in patients with ischemic heart disease and hyperlipoproteinemia].
Bornemisza P; Csögör I
Rev Med Interna Neurol Psihiatr Neurochir Dermatovenerol Med Interna; 1978; 30(6):543-6. PubMed ID: 34860
[No Abstract] [Full Text] [Related]
28. Norethindrone acetate, postheparin lipolytic activity, and plasma triglycerides in familial types I, 3, IV, and V hyperlipoproteinemia. Studies in 26 patients and 5 normal persons.
Glueck CJ; Levy RI; Fredrickson DS
Ann Intern Med; 1971 Sep; 75(3):345-52. PubMed ID: 5568147
[No Abstract] [Full Text] [Related]
29. Increased glucose disappearance rate after short-term clofibrate administration in normal subjects and in patients with chemical diabetes.
Ferrari C; Testori GP; Bertazzoni A; Romussi M; Caldara R; Frezzati S
Horm Metab Res; 1978 Jan; 10(1):4-6. PubMed ID: 631736
[TBL] [Abstract][Full Text] [Related]
30. Plasma lipoproteins, glucose tolerance and insulin response in primary gout.
Wiedemann E; Rose HG; Schwartz E
Am J Med; 1972 Sep; 53(3):299-307. PubMed ID: 5054722
[No Abstract] [Full Text] [Related]
31. Lipoproteins and the relative importance of plasma cholesterol and triglycerides in peripheral arterial disease.
Newall RG; Bliss BP
Angiology; 1973 May; 24(5):297-302. PubMed ID: 4350611
[No Abstract] [Full Text] [Related]
32. The effects of clofibrate on plasma glucose, lipoproteins, fibrinogen, and other biochemical and haematological variables in patients with mature onset diabetes mellitus.
Calvert GD; Blight L; Franklin J; Oliver J; Wise P; Gallus AS
Eur J Clin Pharmacol; 1980 May; 17(5):355-62. PubMed ID: 6998709
[No Abstract] [Full Text] [Related]
33. Glucose kinetics and fatty acids in dogs on matched insulin infusion after glucose load.
Vranic M; Fono P; Kovacevic N; Lin BJ
Metabolism; 1971 Oct; 20(10):954-67. PubMed ID: 5097683
[No Abstract] [Full Text] [Related]
34. [Clofibrate and carbohydrate metabolism: behavior of blood insulin in patients with blood lipid disorders].
Ceruso D; Frisina N; Nicita-Mauro V
Boll Soc Ital Cardiol; 1975; 20(11):1439-47. PubMed ID: 1234442
[No Abstract] [Full Text] [Related]
35. [Influence of fat or carbohydrate rich diet on the serum lipoprotein pattern of a child with primary hypertriglyceridemia (type V hyperlipoproteinemia according to Frederickson) (author's transl)].
Müller WD; Kostner GM
Wien Klin Wochenschr; 1974 Dec; 86(24):757-62. PubMed ID: 4439935
[No Abstract] [Full Text] [Related]
36. The effect of clofibrate on glucose tolerance, insulin secretion, triglycerides and fibrinogen in patients with coronary heart disease.
Enger SC; Johnsen V; Samuelsen A; Laws EA
Acta Med Scand; 1977; 201(6):563-6. PubMed ID: 327758
[TBL] [Abstract][Full Text] [Related]
37. [Serum beta-lipoprotein curve in type II and IV hyperlipoproteinemia after glucose loading].
Plamieniak Z; Amalowicz B; Liebhart J
Pol Tyg Lek; 1972 Jan; 27(1):13-5. PubMed ID: 5060023
[No Abstract] [Full Text] [Related]
38. Effect of clofibrate on glucose tolerance in maturity onset diabetes.
Barnett D; Craig JG; Robinson DS; Rogers MP
Br J Clin Pharmacol; 1977 Aug; 4(4):455-8. PubMed ID: 901737
[TBL] [Abstract][Full Text] [Related]
39. Familial type IV hyperlipoproteinemia.
Schreibman PH; Wilson DE; Arky RA
N Engl J Med; 1969 Oct; 281(18):981-5. PubMed ID: 5824739
[No Abstract] [Full Text] [Related]
40. [Influence of caffein on the daily profile of metabolites from lipid and carbohydrate metabolism as well as of insulin secretion].
Siedek H; Hammerl H; Henk W; Köhn HD; Kränzl C; Nebosis G; Pichler O; Studlar M
Verh Dtsch Ges Inn Med; 1971; 77():606-10. PubMed ID: 5155907
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
